To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad treatment during the acute phase will increase the pain level, the recurrence rate of gout, and the inflammatory level of patients.
Male or female individuals aged 18-70 years old.
Meet the 2015 ACR/EULAR diagnostic criteria of gout.
With an onset of acute gout flares within 7 days.
With gout experiencing gout flares ≥2 times; or with gout experiencing gout flares 1 time and is younger than 40 years old; or with gout experiencing gout flares 1 time and has a serum uric acid level greater than 480 μmol/L and/or has co-morbidities (renal function impairment, hypertension,).
Has secondary hyperuricemia.
Serum uric acid level < 360 μmol/L.
Used IL-1β inhibitors within 6 months before screening.
Used uric acid-lowering drugs within 1 month before screening.
First Affiliated Hospital of Wenzhou Medical University
Lead sponsor
The Affiliated People's Hospital of Ningbo University
Collaborator
Wenzhou Central Hospital
Collaborator
Yuyao People's Hospital
Collaborator